Related Experiment Video
Updated: May 9, 2025
14:25
Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time
Published on: May 20, 2014
17.3K
Endometrioid borderline ovarian tumour: A multicentre analysis from the MITO-14 study
G Candotti1, A Bergamini1, M Perrone2
1Department of Obstetrics and Gynecology, IRCCS San Raffaele Hospital, Milan, Italy.
Summary
Endometrioid Borderline ovarian tumors (EBOT) generally have a good prognosis, with most cases being early-stage and unilateral. Fertility-sparing surgery (FSS) is a viable option when performed by experienced surgeons.
Area of Science:
- Gynecologic Oncology
- Pathology
- Reproductive Medicine
Background:
- Endometrioid Borderline ovarian tumor (EBOT) is the third most common subtype of borderline ovarian tumors.
- Limited literature exists on EBOT prognosis and management due to its low incidence.
- The Multicenter Italian Trials in Ovarian Cancer (MITO) group aimed to clarify EBOT characteristics.
Purpose of the Study:
- To evaluate the clinical and surgical characteristics of EBOT patients.
- To assess the risk of recurrence in EBOT.
- To analyze data from the MITO group's experience.
Main Methods:
- Retrospective collection of clinicopathological data from EBOT patients.
- Descriptive statistics to characterize the patient population.
- Evaluation of clinicopathological features and treatment variables for association with relapse.
Main Results:
- Fifty-six patients with EBOT were analyzed; median age was 49 years.
- 34% had a history of endometriosis; 87% had unilateral tumors.
- No disease-specific deaths occurred; 4 patients (7%) experienced recurrence during median 89-month follow-up.
Conclusions:
- EBOT exhibits a favorable prognosis, with most tumors being Stage I and unilateral.
- Fertility-sparing surgery (FSS) is feasible and safe when performed by experienced surgeons.
- Uterine curettage is recommended if uterine preservation is pursued.
